Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs VanEck Junior Gold Miners (GDXJ) Price & Performance

AbCellera Biologics IncTrade
VanEck Junior Gold MinersTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs VanEck Junior Gold Miners — how do they compare? AbCellera Biologics Inc trades at $10.35 (market cap $2.99B), while VanEck Junior Gold Miners trades at $119.92. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.

ABCLGDXJ
Market Cap
$2.99B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$9.76$156.19
52-Week Low
$2.78$71.22
Enterprise Value
$2.58B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.

The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.

VanEck Junior Gold Miners

GDXJ (VanEck Junior Gold Miners ETF) trades at $119.44, up 0.56% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed sentiment with institutional selling by Amundi reducing its stake by 50.5% in the latest quarter (Defense World, August 6, 2026). Recent underperformance versus peers and gold ETFs highlights challenges in the junior gold mining sector.

Outlook remains cautious due to high RSI levels suggesting overbought conditions and sector-specific headwinds. Investment opportunity hinges on gold price momentum, but risks include Federal Reserve policy uncertainty and competitive pressure from senior miners. Analyst sentiment is neutral with concerns about portfolio composition and small-cap exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About VanEck Junior Gold Miners

GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.

Read more on GDXJ